Overview
Advanced technology such as artificial intelligence, robotics, and natural language processing is penetrating and spreading healthcare product development, while use of eSource and digital devices supports digital data flow and suggests a new clinical trial methodology. Standardization to CDISC is envisioned by 2020 upon full implementation of eData submission, and, combined with the Common Protocol Template proposal, is also helping to lead the standardization and digitalization of end-to-end data flow.
Investigator-initiated trials and collaboration between academia and industry continue to increase as advanced and translational medical technologies such as regenerative and genetic medicine are more deeply incorporated into medical practice in Japan. The impact of these advanced technologies on approaches to drug and device development remains undetermined.
Are clinical data managers (CDMs) ready to ensure the quality of their data through Quality by Design (QbD) as ICH E6(R2) and E8 are being implemented and the “GCP Revolution” is openly discussed? What actions must CDMs take to extend the Risk-Based Approach from clinical trial design to clinical trial reporting and beyond, to post-market safety monitoring? Our overall theme Clinical Data Management in New Era: Enhance Data Reliability and Utilization to Adapt to Renovation reflects the fact the range of clinical trial types and data sources are rapidly expanding. We will collaboratively discuss how CDMs can enhance data reliability and utilization for various clinical trial designs and data sources throughout the drug and/or device product lifecycle, including post-market monitoring. It aims to improve the quality of both clinical research and clinical data management in Japan, and will provide numerous opportunities for networking and information exchange among industry, government, and academia.
Who should attend?
- Clinical data managers
- Clinical research coordinators
- Biostatisticians
- Clinical development professionals
- Information technology professionals
- QC/QA professionals
- Regulatory affairs professionals
- Postmarketing surveillance professionals
Program Committee
-
Motohide Nishi, MBA • Vice President, APAC Professional Services and Customer Care
Medidata Solutions K.K., Japan -
Mika Ogasawara • Quality Lead, Biometrics and Data Management
Pfizer R&D Japan, Japan -
Yukiko Nagata • Associate Director, Clinical Data Management & Technology
Takeda PRA Development Center KK, Japan -
Hitoshi Ozawa, MPharm • GCP Inspector, Office of Non-Clininical and Clinical Compliance
Pharmaceuticals and Medical Devices Agency (PMDA), Japan -
Yasuharu Shibata • Associate Director, Cliinical Data Management
MSD K.K., Japan -
Keisuke Utsumi • Head, Clinical Platforms & Sciences, Japan Development
GlaxoSmithKline K.K., Japan -
Yukikazu Hayashi • Exective director, Datascience Division, Associate Director,
A2 Healthcare Corporation, Japan -
Akimitsu Ikeura, MSc • Associate Director, Data Management Group, Biostatistics & Data Management Dept.
Daiichi Sankyo Co., Ltd., Japan -
Misato Kuwagaki, MS • Consultant, Clinical Laboratory and Data Sciences-eSource/Clinilcal Risk
Eli Lilly Japan K.K., Japan -
Kyoko Minamoto • Medical Technologist
National Cancer Center, Japan -
Tempei Miyaji, MSc • Project Assistant Professor, Department of Clinical Trial Data Management
The University of Tokyo Hosptial, Japan -
Yumi Sugiura, MRCP • Global Clinical Operations, Global Data Management and Centralized Monitoring
Bristol-Myers Squibb K.K., Japan -
Yumiko Asami • Statistician, Manager, Electronic Data System Management Group, Biostatistics &
Daiichi Sankyo Co., Ltd., Japan
